Cancer News: Prostate
Prostate cancer patients treated with testosterone-lowering drugs are more likely to develop dementia.
Brachytherapy alone can give similar results & fewer side-effects in mid-risk prostate cancer compared to its combination with external beam therapy (EBT).
Oncology trials show similar outcomes and side effects for early stage prostate cancer with conventional and hypo-fractionated radiotherapy.
A randomized trial proved the importance of joint decision making between prostate cancer patients and physicians during the treatment selection process.
Prostate cancer patients undergoing robotic surgery experienced similar quality of life compared to those undergoing open surgery, a trial reveals.
Very high-risk prostate cancer patients treated with a high proportion of radical local treatment survived longer, according to a new study.
The inhibitor cabozantinib failed to induce significant benefit in prostate cancer patients, a phase 3 trial reveals.
A diagnosis of high cholesterol led to reduced mortality and improved survival in lung, breast, prostate and bowel cancer, a new researches reveals.
Adding radiotherapy to androgen deprivation therapy in the treatment of metastatic prostate cancer patients prolonged survival more, an analysis reveals.
Robotic surgery to remove the prostate reduced risk of blood loss in obese prostate cancer patients, a new study reveals.
Prostate cancer patients who had a healthy communication with their physicians improved their health-related quality of life, according to a study.
Physicians should not hesitate to prescribe testosterone therapy to men as it will not increase their risk of prostate cancer, a new study shows.
Moderate to high level of physical activity may improve survival prognosis of prostate cancer patients, a new study reports.
Treating prostate cancer patients with stereotactic body radiation (SBRT) therapy induced positive results, a new study reveals.
Prostate cancer patients treated with short-course androgen deprivation therapy plus bevacizumab had a longer relapse-free interval, a small study shows.
Early-stage prostate cancer patients can be given a shorter and slightly higher daily dose of radiation with no difference in overall survival, a study shows.
Abiraterone acetate increased overall survival in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer.
A new large study reported that the location where prostate cancer spreads has an impact on the patient’s survival time.
A report on active surveillance of low-risk prostate cancer patients clarifies who should undergo "active surveillance” instead of prostatectomy or radiation.
Docetaxel chemotherapy will be made available to newly diagnosed advanced prostate cancer patients in England, the NHS has announced.
A study comparing enzalutamide to bicalutamide in castration-resistant prostate cancer showed that enzalutamide increased significantly progression-free survival.
Treating patients with castration-resistant metastatic prostate cancer with docetaxel following abiraterone resulted in a 50% reduction in prostate specific antigen.
Treating high-risk prostate cancer patients with anti-androgen therapy using daily bicalutamide improved their overall survival, a new research reveals.
A study comparing surgical to chemical castration in men with metastatic prostate cancer showed that surgical castration leads to less adverse effects.
Scientists reveal that very few low-risk prostate cancer patients followed by watchful waiting are closely monitored as called for in current guidelines.
Prostate cancer patients playing soccer a few times a week improved muscular strength and bone density, tackling treatment-related side effects.
Taking intensive yoga classes helped patients undergoing prostate cancer treatment improve their general well-being, a new research shows.
Olaparib, a drug against inherited cancer mutations, was found to benefit as many as a third of patients with prostate cancer, a new study reveals.
A shorter radiation therapy schedule was equally beneficial as a longer treatment schedule for some men with low-risk prostate cancer.
A new long-term study showed that treatment was unnecessary for the majority of older men diagnosed with low-risk prostate cancer and under an active surveillance scheme.